Cover Image
市場調查報告書

Ganymed Pharmaceuticals AG的產品平台分析

Ganymed Pharmaceuticals AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 289828
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Ganymed Pharmaceuticals AG的產品平台分析 Ganymed Pharmaceuticals AG - Product Pipeline Review - 2015
出版日期: 2015年02月24日 內容資訊: 英文 32 Pages
簡介

Ganymed Pharmaceuticals AG,是開發治療實體癌之單株抗體的生物醫藥品企業。

本報告提供Ganymed Pharmaceuticals AG的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Ganymed Pharmaceuticals AG概要

  • 概要
  • 企業資料
  • 主要資訊

Ganymed Pharmaceuticals AG:R&D概要

  • 主要的治療範圍

Ganymed Pharmaceuticals AG:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Ganymed Pharmaceuticals AG:開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 藥物研發中的產品/聯合治療模式

Ganymed Pharmaceuticals AG:藥物簡介

  • IMAB-362
  • IMAB-027
  • Bispecific Monoclonal Antibodies to Inhibit CLDN6 for Solid Tumor
  • Conjugated Monoclonal Antibodies to Inhibit CDLN18.2 for Solid Tumors
  • Conjugated Monoclonal Antibodies to Inhibit CLDN6 for Solid Tumors
  • Monoclonal Antibodies to Inhibit CDLN18.2 for Solid Tumors
  • Monoclonal Antibodies to Inhibit GT-468 for Oncology
  • Monoclonal Antibodies to Target GT-352 for Solid Tumors
  • Monoclonal Antibodies to Target GT-353 for Solid Tumors

Ganymed Pharmaceuticals AG:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Ganymed Pharmaceuticals AG:最新的開發中產品資訊

Ganymed Pharmaceuticals AG:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06792CDB

Summary

Global Markets Direct's, 'Ganymed Pharmaceuticals AG - Product Pipeline Review - 2015', provides an overview of the Ganymed Pharmaceuticals AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ganymed Pharmaceuticals AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Ganymed Pharmaceuticals AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Ganymed Pharmaceuticals AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Ganymed Pharmaceuticals AG's pipeline products

Reasons to buy

  • Evaluate Ganymed Pharmaceuticals AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Ganymed Pharmaceuticals AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Ganymed Pharmaceuticals AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Ganymed Pharmaceuticals AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ganymed Pharmaceuticals AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Ganymed Pharmaceuticals AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Ganymed Pharmaceuticals AG Snapshot
    • Ganymed Pharmaceuticals AG Overview
    • Key Information
    • Key Facts
  • Ganymed Pharmaceuticals AG - Research and Development Overview
    • Key Therapeutic Areas
  • Ganymed Pharmaceuticals AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Ganymed Pharmaceuticals AG - Pipeline Products Glance
    • Ganymed Pharmaceuticals AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Ganymed Pharmaceuticals AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Ganymed Pharmaceuticals AG - Drug Profiles
    • IMAB-362
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IMAB-027
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GT-352
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GT-353
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GT-468
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit CDLN18.2 for Solid Tumors
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit CLDN6 for Solid Tumor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates to Inhibit CDLN18.2 for Solid Tumors
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates to Inhibit CLDN6 for Solid Tumors
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ganymed Pharmaceuticals AG - Pipeline Analysis
    • Ganymed Pharmaceuticals AG - Pipeline Products by Target
    • Ganymed Pharmaceuticals AG - Pipeline Products by Route of Administration
    • Ganymed Pharmaceuticals AG - Pipeline Products by Molecule Type
    • Ganymed Pharmaceuticals AG - Pipeline Products by Mechanism of Action
  • Ganymed Pharmaceuticals AG - Recent Pipeline Updates
  • Ganymed Pharmaceuticals AG - Locations And Subsidiaries
  • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Ganymed Pharmaceuticals AG, Key Information
  • Ganymed Pharmaceuticals AG, Key Facts
  • Ganymed Pharmaceuticals AG - Pipeline by Indication, 2015
  • Ganymed Pharmaceuticals AG - Pipeline by Stage of Development, 2015
  • Ganymed Pharmaceuticals AG - Monotherapy Products in Pipeline, 2015
  • Ganymed Pharmaceuticals AG - Phase II, 2015
  • Ganymed Pharmaceuticals AG - Phase I, 2015
  • Ganymed Pharmaceuticals AG - Preclinical, 2015
  • Ganymed Pharmaceuticals AG - Discovery, 2015
  • Ganymed Pharmaceuticals AG - Pipeline by Target, 2015
  • Ganymed Pharmaceuticals AG - Pipeline by Route of Administration, 2015
  • Ganymed Pharmaceuticals AG - Pipeline by Molecule Type, 2015
  • Ganymed Pharmaceuticals AG - Pipeline Products by Mechanism of Action, 2015
  • Ganymed Pharmaceuticals AG - Recent Pipeline Updates, 2015

List of Figures

  • Ganymed Pharmaceuticals AG - Pipeline by Top 10 Indication, 2015
  • Ganymed Pharmaceuticals AG - Pipeline by Stage of Development, 2015
  • Ganymed Pharmaceuticals AG - Monotherapy Products in Pipeline, 2015
  • Ganymed Pharmaceuticals AG - Pipeline by Top 10 Target, 2015
  • Ganymed Pharmaceuticals AG - Pipeline by Top 10 Route of Administration, 2015
  • Ganymed Pharmaceuticals AG - Pipeline by Top 10 Molecule Type, 2015
  • Ganymed Pharmaceuticals AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top